Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens (Q41560158)

3 October 2017

1 reference

title

Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens (English)

1 reference

3 October 2017

1 reference

de Cupis A

1

1 reference

PubMed ID

9253856

3 October 2017

Favoni RE

series ordinal

2

1 reference

3 October 2017

1 July 1997

1 reference

Trends in Pharmacological Sciences

3 October 2017

1 reference

3 October 2017

18

1 reference

3 October 2017

7

1 reference

3 October 2017

245-251

1 reference

UICC Multidisciplinary Project on Breast Cancer: the epidemiology, aetiology and prevention of breast cancer

3 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Recent trends in breast cancer incidence, mortality, and mammography

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Hormone resistance, invasiveness, and metastatic potential in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Autocrine and paracrine growth regulation of breast cancer: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Mitogenic signal transduction in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Structure and function of the estrogen receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Estrogen receptor interaction with specific histones. Binding to genomic DNA and an estrogen response element

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Action of "pure" antiestrogens in inhibiting estrogen receptor action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Autocrine regulation of membrane transforming growth factor-alpha cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Expression of transforming growth factor beta mRNA isoforms in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

A secreted glycoprotein induced by estrogen in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Reduced levels of cathepsin D associated with tamoxifen resistance and estrogen independence in the ZR-75-1 human breast cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

The epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Fibroblast-growth-factor receptor mutations in human skeletal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Signal transduction by the PDGF receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Insulin-like growth factors and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Insulin-like growth factor expression in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Matrix-degrading proteases in hormone-dependent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Oestrogens, proteases and breast cancer. From cell lines to clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Chemoprevention of breast cancer by tamoxifen: risks and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

An overview of considerations for the testing of tamoxifen as a preventive for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Alternative mechanisms of action of anti-oestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Clinical potential of new antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Novel steroidal pure antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Therapeutic potential of pure antioestrogens in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

The future of new pure antiestrogens in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Novel antioestrogens without partial agonist activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901083-3

7 January 2021

10.1016/S0165-6147(97)01083-3

Identifiers

DOI

1 reference

3 October 2017

1 reference

PubMed ID

9253856